Detalles de la búsqueda
1.
The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study.
Breast Cancer Res Treat
; 203(3): 497-509, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37938495
2.
Essential medicines list in national cancer control plans: a secondary analysis from a global study.
Lancet Oncol
; 23(3): e144-154, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35240089
3.
Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO study.
Br J Cancer
; 127(10): 1799-1807, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36050448
4.
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.
J Thorac Oncol
; 12(4): 752-762, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28017787
5.
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.
Lancet Respir Med
; 5(5): 435-444, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28408243
6.
Statistical methods for the analysis of clinical trials data containing many zeros: An application in vaccine development.
Stat Methods Med Res
; 25(6): 2811-2826, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-24845724
Resultados
1 -
6
de 6
1
Próxima >
>>